Drugs / MTB-9655
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04990739 | Jun 2021 → Jan 2024 | neoplasm | MetaboMed Inc | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTB-9655 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990739 ↗ |
| Action | Inhibit | “small molecule inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 (ACSS2) enzyme” NCT04990739 ↗ |
| Modality | Small molecule | “first-in-class small molecule inhibitor” NCT04990739 ↗ |
| Route | Oral | “MTB-9655, by mouth daily” NCT04990739 ↗ |
| Target | ACSS2 | “inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 (ACSS2) enzyme” NCT04990739 ↗ |